Key result
Strategies for organ-specific mRNA delivery using lipid nanoparticles include new lipid structures, targeting ligands, and formulation optimization to expand therapeutics beyond liver diseases.
Why the study?
Most lipid nanoparticle formulations predominantly target the liver, limiting their application for nonliver diseases.
This review highlights advancements in lipid nanoparticle formulations to enable organ-specific mRNA delivery beyond the liver, expanding the potential of mRNA therapeutics.
Answers are grounded in this paper and cite their sources.
Organ-specific LNP-mRNA delivery remains preclinical; leaves open translation beyond hepatic targets pending targeted trials.
Messenger RNA (mRNA) technology has rapidly evolved, significantly impacting various therapeutic applications, including vaccines, protein replacement, and gene editing. Lipid nanoparticles (LNPs) have emerged as a pivotal nonviral vector for mRNA delivery, crucial for organ-targeted therapies. Despite their success, most LNP formulations predominantly target the liver, limiting their use in nonliver diseases. This review explores strategies to achieve organ-specific mRNA delivery using LNPs, including the discovery of new lipid structures, modification of targeting ligands, incorporation of additional components, and optimization of LNP formulations. These advancements aim to enhance the precision and efficacy of mRNA therapeutics across a broader range of diseases.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2024) reported a review. Organ-targeted mRNA delivery by lipid nanoparticles was evaluated. Strategies for organ-specific mRNA delivery using lipid nanoparticles include new lipid structures, targeting ligands, and formulation optimization to expand therapeutics beyond liver diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: